ES2174834T3 - Compuestos oligomericos aromaticos utiles como mimeticos de macromoleculas bioactivas. - Google Patents

Compuestos oligomericos aromaticos utiles como mimeticos de macromoleculas bioactivas.

Info

Publication number
ES2174834T3
ES2174834T3 ES92912715T ES92912715T ES2174834T3 ES 2174834 T3 ES2174834 T3 ES 2174834T3 ES 92912715 T ES92912715 T ES 92912715T ES 92912715 T ES92912715 T ES 92912715T ES 2174834 T3 ES2174834 T3 ES 2174834T3
Authority
ES
Spain
Prior art keywords
oligomeric compounds
compounds useful
mimetics
disorders
bioactive macromolecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92912715T
Other languages
English (en)
Inventor
John R Regan
Daniel G Mcgarry
Michael N Chang
Jeffrey N Barton
Jack Newman
Schmuel Ben-Sasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer International Holdings Inc
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Application granted granted Critical
Publication of ES2174834T3 publication Critical patent/ES2174834T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G8/00—Condensation polymers of aldehydes or ketones with phenols only
    • C08G8/04—Condensation polymers of aldehydes or ketones with phenols only of aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyamides (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS OLIGOMERICOS UTILES EN EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES, METABOLICOS DE LOS HUESOS, HIPOLIPIDEMICOS, NEURONALES GASTROINTESTINALES Y DE LOS TEJIDOS CONJUNTIVOS MEDIANTE ELASTADAS Y TRASTORNOS QUE PUEDEN SER TRATADOS POR AGENTES EFICACES EN EL ENLACE DE ADN, O PROLIFERACION DE CELULAS DE MUSCULOS BLANDOS ANORMALES, A PROCESOS PARA LA PREPARACION DE TALES COMPUESTOS OLIGOMERICOS, A COMPOSICIONES FARMACEUTICOS QUE COMPRENDEN TALES COMPUESTOS OLIGOMERICOS, Y SU USO EN EL TRATAMIENTO DE TALES TRASTORNOS.
ES92912715T 1991-05-20 1992-05-20 Compuestos oligomericos aromaticos utiles como mimeticos de macromoleculas bioactivas. Expired - Lifetime ES2174834T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70306191A 1991-05-20 1991-05-20

Publications (1)

Publication Number Publication Date
ES2174834T3 true ES2174834T3 (es) 2002-11-16

Family

ID=24823810

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92912715T Expired - Lifetime ES2174834T3 (es) 1991-05-20 1992-05-20 Compuestos oligomericos aromaticos utiles como mimeticos de macromoleculas bioactivas.

Country Status (8)

Country Link
EP (1) EP0585371B1 (es)
AT (1) ATE216247T1 (es)
AU (1) AU2010792A (es)
DE (1) DE69232557T2 (es)
DK (1) DK0585371T3 (es)
ES (1) ES2174834T3 (es)
MX (1) MX9202389A (es)
WO (1) WO1992020350A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139025D1 (de) 2000-12-28 2009-07-30 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
EP1394154A4 (en) 2001-03-23 2005-05-18 Takeda Pharmaceutical FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
AU2019234670B2 (en) 2018-03-13 2023-11-23 Takeda Pharmaceutical Company Limited Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
EP4477220A3 (en) 2019-09-18 2025-02-26 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
WO2023166346A1 (en) 2022-03-02 2023-09-07 Horizon Therapeutics Ireland Dac Process of making a crystalline edg-2 receptor antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2323481A (en) * 1939-03-14 1943-07-06 Du Pont Chemical process and composition
US2910484A (en) * 1957-05-09 1959-10-27 Ciba Pharm Prod Inc Polyhydric-aldehyde condensation products
US4604404A (en) * 1985-04-03 1986-08-05 A. H. Robins Company, Inc. Antiviral sulfonated naphthalene formaldehyde condensation polymers
IL95353A (en) * 1989-08-14 1995-01-24 Rhone Poulenc Rorer Int Pharmaceutical preparations containing aromatic polymers
EP0502117B1 (en) * 1989-11-22 1999-06-23 Rhone-Poulenc Rorer International (Holdings) Inc. Pharmaceutical compositions comprising polymers with alkyl- or heteroalkyl-aryl backbone
FR2672214A1 (fr) * 1991-01-31 1992-08-07 Rhone Poulenc Rorer Sa Application de polymeres biologiquement actifs, pour l'obtention d'un medicament pour le traitement d'infections a retrovirus.

Also Published As

Publication number Publication date
EP0585371A4 (en) 1994-07-13
EP0585371A1 (en) 1994-03-09
DE69232557D1 (de) 2002-05-23
ATE216247T1 (de) 2002-05-15
EP0585371B1 (en) 2002-04-17
DE69232557T2 (de) 2002-10-24
WO1992020350A1 (en) 1992-11-26
MX9202389A (es) 1993-08-01
AU2010792A (en) 1992-12-30
DK0585371T3 (da) 2002-08-12

Similar Documents

Publication Publication Date Title
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
DK1133989T3 (da) Polymersammensætning til anvendelse i terapi
ATE298790T1 (de) Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
EP2497478A3 (en) Oligosaccaride compositions and use thereof in the treatment of infection
ATE316786T1 (de) Behandlung von mukositis
WO2004019884A3 (en) Agents and methods for enhancing bone formation
WO2001068135A3 (en) Compositions and methods for affecting osteogenesis
ES2174834T3 (es) Compuestos oligomericos aromaticos utiles como mimeticos de macromoleculas bioactivas.
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
EP2096120A3 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
RU98114982A (ru) Состав, содержащий диосгенин
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
GR3020232T3 (en) LOW-MOLECULAR SULPHATED POLY--g(b)-2,6-FRUCTOFURANOSANES AND THEIR USE IN THE TREATMENT OF DEGENERATIVE ARTICULAR AILMENTS
WO2000030669A3 (en) Use of plasma phospholipid transfer proteins in treating cardiovascular dieases

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 585371

Country of ref document: ES